Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10322591 | 1.00 | TDP1 (0.56) | TDP1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL11046054 | 0.82 | TP53 (0.44) | TDP1ALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL15050572 | 0.82 | TP53 (0.44) | TDP1ALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL30374990 | 0.82 | TP53 (0.44) | TDP1ALDH1A1GABRA1GABRG2GABRB3 | |
| SCHEMBL11454521 | 0.81 | TDP1 (0.60) | TDP1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL705623 | 0.81 | TDP1 (0.60) | TDP1MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL23347609 | 0.80 | GABRA1 (0.49) | TDP1ALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL14817563 | 0.80 | CYP3A4 (0.40) | TDP1MAPTALDH1A1KDM4EGAA | |
| SCHEMBL21608947 | 0.80 | CYP3A4 (0.40) | TDP1MAPTALDH1A1KDM4EGAA | |
| SCHEMBL1689790 | 0.79 | TDP1 (0.58) | TDP1MAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| EP-2970112-B1 | PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-03-12 | — | — | EP | disclosed |
| EP-2968210-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY | BIO PHARM SOLUTIONS CO LTD (KR) | 2024-09-11 | — | — | EP | disclosed |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-111419830-B | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes | 比皮艾思药物研发有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4204395-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-115996905-A | Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases | 生物药品解决方案有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-109939092-B | Phenyl carbamate compounds for use in preventing or treating pediatric epilepsy and epilepsy-related syndrome | 比皮艾思药物研发有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109071424-B | Sulfamate derivative compound, preparation method and application thereof | 生物药品解决方案有限公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| WO-2012096458-A2 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012002773-A2 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-01-05 | — | — | WO | disclosed |
| US-20100189795-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | NEOCUTIS S.A. (CH) | 2010-07-29 | — | — | US | disclosed |
| US-7326727-B2 | Furanthiazole derivatives as heparanase inhibitors | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2008-02-05 | — | — | US | disclosed |
| US-7326727-B2 | Furanthiazole derivatives as heparanase inhibitors | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2008-02-05 | — | — | US | disclosed |
| EP-0104863-B1 | LIGHT-SENSITIVE PLANOGRAPHIC PRINTING PLATE | FUJI PHOTO FILM CO., LTD. (JP) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189795-A1 | CALCIUM SEQUESTRATION COMPOSITIONS AND METHODS OF TREATING SKIN PIGMENTATION DISORDERS AND CONDITIONS | S100A4, TYR, CACYBP | TDP1 2370/4885MAPT 921/4885ALDH1A1 2945/4885 |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | CPT1B, MYLK, PYGM | TDP1 1503/4885MAPT 536/4885ALDH1A1 3483/4885 |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | SNCA, MAPT, CHAT | TDP1 973/4885MAPT 2/4885ALDH1A1 1826/4885 |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | CPS1, BCHE, ACHE | TDP1 459/4885MAPT 176/4885ALDH1A1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.